ANCOBON PRESCRIBING INFORMATION PDF

Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.

Author: Muzragore Saran
Country: Estonia
Language: English (Spanish)
Genre: Career
Published (Last): 16 April 2017
Pages: 312
PDF File Size: 7.25 Mb
ePub File Size: 19.74 Mb
ISBN: 488-9-93022-686-5
Downloads: 60986
Price: Free* [*Free Regsitration Required]
Uploader: Grogar

The risk or severity of adverse effects can be increased when Flucytosine is combined with Idelalisib. Most strains of C.

The risk or severity of bleeding can be increased when Linsidomine is combined with Flucytosine. The risk or severity of adverse effects can be increased acnobon Penicillamine is combined with Flucytosine. The flucytosine metabolite 5-fluorouracil is genotoxic in mice and in vitro, embryotoxic and teratogenic in mice and rats, and is classified as possible human teratogen.

Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Flucytosine. S -Warfarin The risk or severity of bleeding can be increased when Flucytosine is pgescribing with S -Warfarin. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.

For persistence or relapse of cryptococcosis, reinstate induction therapy for 4 to 10 weeks. Close monitoring is necessary during flucytosine therapy. In cases where renal impairment is present the dose interval should be extended as with adults and children. The risk or severity of adverse effects can be increased when Flucytosine is combined with Obinutuzumab.

  GRANTHA ALPHABET PDF

The risk or severity of adverse effects can be increased when Flucytosine is combined with Wortmannin.

The risk or severity of adverse ibformation can be increased when Amsacrine is combined with Flucytosine. Acenocoumarol The risk or severity of bleeding can be increased when Flucytosine is combined with Acenocoumarol. Fungi that usually are susceptible include: Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flucytosine.

Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Flucytosine.

ANCOBON Dosage & Rx Info | Uses, Side Effects – MPR

The risk or severity of adverse effects can be increased when Flucytosine is combined with Abatacept. The dose in neonates should be calculated in the same way as for adults and children, but the high possibility of renal impairment should be considered in this group either as intrinsic to their age or as a result of other nephrotoxic therapies.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Gallium nitrate. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Flucytosine. Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Flucytosine.

  KAREN MACINERNEY ON THE PROWL PDF

PDR Search

The risk or severity of bleeding can be increased when Tenecteplase is combined with Flucytosine. Send the page ” ” to a friend, relative, colleague or yourself. The risk or severity of adverse effects can be increased when Carmustine is combined with Flucytosine. The product should be used with great caution in patients with depression of bone marrow function or blood dyscrasias.

Flucytosine

Frequently monitor blood counts during flucytosine therapy. Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flucytosine. Levomefolic acid The risk or severity of adverse effects can be increased when Levomefolic acid is combined with Flucytosine. Tositumomab Prdscribing risk or severity of adverse effects can be increased when Tositumomab is combined with Flucytosine.

The following is suggested as a guide for dosage in patients with severe infection associated with renal impairment:. Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Flucytosine. Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Flucytosine. Prescriibing biscoumacetate The risk or severity of bleeding infromation be increased when Flucytosine is combined with Ethyl biscoumacetate.